Long-term treatment outcome of type 1 thyroplasty using novel titanium medialization laryngoplasty implant combined with arytenoid adduction for unilateral vocal cord paralysis: single-arm interventional study at a single institution.

Abstract

OBJECTIVE:

To evaluate the long-term treatment outcome of type 1 thyroplasty with novel rearrangeable titanium medialization laryngoplasty implant (TMLI) combined with arytenoid adduction (AA) for unilateral vocal cord paralysis (UVFP) in the authors' institution.

METHODS:

A total of 16 Japanese patients with UVFP who received type 1 thyroplasty using TMLI with arytenoid adduction was enrolled in this single-arm, non-randomized interventional study. The results of the auditory perceptual assessment, aerodynamic examination, acoustic measurement, and patient-based survey on these patients were evaluated preoperatively and at 3, 6, and 12 months postoperatively.

RESULTS:

Type 1 thyroplasty using TMLI with arytenoid adduction for our patient series presented significant improvements in maximum phonation time, mean flow rates, GRBAS scale, the Voice Handicap Index and the Voice-Related Quality of Life score over the 12-month postoperative period.

CONCLUSION:

Type 1 thyroplasty using TMLI with arytenoid adduction was quite effective for obtaining satisfactory postoperative voice improvement without any surgical complication over the long-term period.

• Authors: Daisuke Sano, Koji Matsushima, Yasuhiro Isono, Yukiko Ikui, Yuri Kinutani, Yoshihiro Chiba, Hajime Hirose, Nobuhiko Oridate
• Journal: Laryngoscope investigative otolaryngology (Laryngoscope Investig Otolaryngol) Vol. 5 Issue 5 Pg. 895-902 (Oct 2020) ISSN: 2378-8038 [Print] United States
• PMID: 33134537 (Publication Type: Journal Article)
• Copyright: © 2020 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.